Innovent bets $250M+ on Union’s PDE4 inhibitor ahead of a PhII readout

A year after plucking orismilast from Leo Pharmaceuticals’ pipeline — and without publishing any mid-stage data — Union Therapeutics is already making a pretty penny on the oral PDE4 inhibitor.

Innovent Biologics is shelling out $20 million upfront for development and commercialization rights to Union’s “Phase III-ready” oral formulation...

Click to view original post